Member Info for Richob

I think they took the MMs names off months ago.

gmcc,

DX is diagnostics and RX is therapeutics.

I think it is from Latin.

Cave Exigo.

Onwards Avacta.

Agree, Timster.

Can't see an RNS before Friday as this would make the "roadshows" unequal.

I do think that we are due an update on the LFT but am happy to await the AVA6000 update as I see that as pivotal.

Key question for me is ....

Why else would they announce AVA3996 as the next Precision drug if AVA6000 wasn't going well?

If anybody has a reason it would be good to hear it. For my "sins" I have been buying at these prices as I don't think they can possibly reflect the value is the Precision and Affimer intellectual property.

Time will tell if I have this right of course.

As ever, onwards Avacta.

Is this him?

https://www.labmate-online.com/news/news-and-views/5/avacta-group/avacta-expands-development-team-in-us/44441

Onwards Avacta

Some good coverage of Affyxell in here:

https://www.trinitydelta.org/research-notes/so-much-more-than-a-play-on-covid-testing/

Onwards Avacta.

I have rephrased the question about what is AVA6000 worth as there appears to be a lack of understanding about what AVA is, or, more precisely, what Precision is.

Precision is a is a delivery system for drugs.

AVA6000 is a trial of the delivery system for doxorubicin, an existing cancer treatment drug.

This is important because the existing delivery of the drug has two main issues:

a) Only certain levels of the drug can be administered.
b) The drug impacts other organs outside of the cancer.

The point of AVA (Precision) is that it delivers the drug directly to the tumour. This means that more of the delivered drug hits the cancer and less hits other organs.

Both mean a greater chance of successful treatment.

In trying to put a value on AVA (Precision), you therefore need to consider Total Available Market.

Now, if the delivery system doesn't work then the value is zero. This is the risk aspect of the share.

However, if the delivery system does work, then the TAM of drug delivery is incalculable as it exceeds the values of all drugs currently being delivered causing side effects. This is the reward aspect of this share.

Avacta is currently trialling a drug delivery system that would revolutionise treatments across a broad range of diseases. That is very hard to value and no doubt of interest to pharmas that sell the current drugs.

Trust this helps and happy if it is called a ramp, which is what all positive posts appear to get named.

Onwards Avacta.

I didn't mean producing the current test but the unaffected relevant parts for the amended test.

Sorry if that wasn't clear.

... but has had me wondering.

Does "postpone sales" mean "postpone production"?

I realise that full production would not be possible without the new antibody but understood that an LFT was made up of parts, such as cassette, buffer, etc.

Don't mind being called dumb if I am being.

Onwards Avacta.

Think it is Advena, Tim.

Happy New Year.

https://www.dailymail.co.uk/news/article-10362195/British-lateral-flow-tests-BANNED-UK-despite-cleared-use-EU.html

TERN might be missing you but we aren't.

Happy New Year in your own share.

... would like to wish all its passengers a happy and prosperous New Year and remind everyone of what you have, or in the case of some passengers, have not, invested in.

Avacta currently has one cancer treatment in human trials in the UK plus a successful IND filing for trials in the US.

Other cancer treatments are in consideration for trials, AVA3996 being the likely next one.

Avacta also has a lateral flow test which detects both Omicron and Delta variants awaiting formal CTDA reapproval with distributors for that test.

The world has been wanting better cancer outcomes for years and is also now short of lateral flow tests, particularly accurate ones.

The company has 254m shares in issue and is currently valued at £315m whilst operating in markets worth billions of pounds.

Other aspects of Avacta include collaborations with major pharmaceutical companies and the renting of intellectual property.

Shares are currently in the 120p to 130p range.

A very happy and prosperous New Year from The Bus Company.

Very well written, ninkynonk.

Onwards Avacta.

Hua

Trinity Delta view the Therapeutics as @80% of the company's value.

Trinity Delta view: The extension of the AVA6000 Phase I study into the US, ahead of our expectations, is an endorsement of Avacta’s clinical team’s efforts and the quality of the preclinical package. Positive outcomes in reducing doxorubicin’s systemic toxicity will be important in establishing proof of concept of the pre|CISION platform. A broader pipeline of pro-drugs whose clinical utility would benefit from improved efficacy and reduced toxicities is being progressed. We value Avacta at £710m, or 280p per share, with the Diagnostic opportunities representing £133m and the Therapeutic pipeline rNPV £559m.

Investor sentiment may believe it is more diagnostic value than therapeutic but I can't see how this moves from 20/80 to 80/20 on the basis of sentiment alone.

Rest easy Mr Ripley.

Onwards Avacta.

Not at all, mowzer.

We have all the top notch brands at the Hip, Hip, Hua bus.

All the best

... is pleased to announce two buses for tomorrow morning.

The first one is the "Troll Down Memory Lane" special, complete with sweet infused windows and crayoning books.

The second one is the "Hip, Hip, Hua", which comes with champagne and smoked salmon sandwiches.

That must cover most posters and I do love a glass of Bolly.

Onwards Avacta.

For anyone reading the discussion board wanting to know about Avacta, the following is quite useful:

https://www.trinitydelta.org/research-notes/so-much-more-than-a-play-on-covid-testing/

Written, I think, before the AVA6000 clinical trial began, it provides a good background to what Avacta offers the industry and its current partners.

Whilst any allocated amounts for each part of the business are subject to debate and challenge, the relevance is that there are a number of parts.

Onwards Avacta.

Is it just my buy showing as a sell?

Looks like it comes under "Best Tech Award".

Good to see the tech recognised across Europe with this nomination.

Abivax won it last year I believe.

Onwards Avacta.